Mobile

A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leuco...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000715-26

A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. To demonstrate that the combination of bevacizumab and FOLFOX-4 is superior to FOLFOX-4 alone in terms of disease-free survival in chemotherapy-naïve patients who underwent surgery with curative intent for colon carcinoma. 2. To demonstrate that the combination of bevacizumab and XELOX is superior to FOLFOX-4 alone in terms of disease-free survival in chemotherapy-naïve patients who underwent surgery with curative intent for colon carcinoma.

Critère d'inclusion

  • Adjuvant treatment for patients who have undergone surgery for Colon cancer, AJCC/UICC high-risk Stage II & stage III

Liens